Lupin Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its manufacturing facility in Goa. The report follows a recent inspection of the site and marks the formal closure of the regulatory review process.

The Goa facility was classified under Voluntary Action Indicated (VAI) status. A VAI classification means that while certain observations were noted during the inspection, they are not severe enough to warrant regulatory enforcement action. The company is expected to address the observations voluntarily while continuing operations.

The Goa plant is an important manufacturing site in Lupin’s global supply network, supplying pharmaceutical formulations to regulated markets, including the United States. Receiving the EIR strengthens the company’s regulatory standing and supports continued product approvals and commercial supplies from the facility.

The development reflects Lupin’s ongoing focus on quality compliance and adherence to current good manufacturing practices (cGMP). Regulatory clearances from the USFDA are critical for Indian pharmaceutical companies with significant exposure to the US generics market.

Lupin, headquartered in Mumbai, operates across more than 100 markets worldwide and manufactures a broad portfolio that includes generic and branded formulations, complex generics, biotechnology products and active pharmaceutical ingredients.